<DOC>
	<DOC>NCT02057523</DOC>
	<brief_summary>The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.</brief_summary>
	<brief_title>Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
	<mesh_term>beta-Endorphin</mesh_term>
	<criteria>Kidney transplant recipients with confirmed transplant glomerulopathy on kidney biopsy. Failed standard therapy (&gt;25% reduction in proteinuria) including maximum use of an ACE inhibitor, ARB, or aldosterone blocker with a goal blood pressure less than 130/80 and optimization of their immunosuppression Diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>